Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed notable progress: a positive End-of-Phase 2 meeting with the FDA, clear Phase III plans and timelines, strong clinical momentum from 2025 data, and a solid cash runway into 2028 to reach key readouts. Key risks include the FDA requirement for a 52-week controlled safety database that delays the 24-week efficacy readout, potential additional DDI requirements if new therapies are approved, uncertainty around orphan designation, and the extended timelines associated with global Phase III execution. On balance, achievements and forward execution plans outweigh the manageable challenges.Company Guidance
Positive End-of-Phase 2 Meeting with FDA
Management reported a collaborative End-of-Phase 2 meeting with the FDA for the IPF-related chronic cough program with alignment on pathway to NDA, primary endpoint (objective cough monitor), and agreement to proceed with 2 pivotal Phase III trials.
Planned Phase III Program and Timelines
Company plans two parallel global Phase III trials for IPF-related chronic cough: a 52-week trial (primary efficacy at 24 weeks, ~300 patients) and a confirmatory 12-week trial (~130 patients) with initiation of the first trial expected in Q2 and the second in H2 of the year.
Strong 2025 Clinical Data Momentum
Positive 2025 readouts from CORAL (IPF chronic cough) and RIVER (refractory chronic cough) trials supported capital raises and enabled progression to registrational programs.
Cash Runway to Fund Key Milestones
Trevi ended 2025 with approximately $188 million in cash, cash equivalents and marketable securities, providing an expected runway into 2028 to reach top-line data for: Phase IIb RCC, Phase IIb non-IPF chronic cough and the 12-week pivotal Phase III IPF readout.
Market Opportunity and Addressable Patient Populations
Estimated U.S. IPF population of ~150,000 with ~2/3 (≈66.7%) having uncontrolled chronic cough; non-IPF ILD estimated at ~228,000 with 50%–60% (≈114k–136.8k) having uncontrolled cough — more than doubling the market opportunity beyond IPF alone.
RCC and Dose Optimization Strategy
Planned Phase IIb parallel-arm dose-ranging RCC trial (3 doses + placebo) to determine dosing; crossover data suggest activity at low dose and interest in exploring lower or once-daily dosing and related IP/formulation strategies.
Operational Readiness and Enrollment Expectations
Management expects enrollment for the larger Phase III to take ~1 year with ~80–100 sites (majority U.S.); strong physician and site interest reported and plans for patient advocacy engagement to support recruitment.
Secondary Endpoints and Patient-Reported Outcomes
Primary objective cough monitor retained; key secondary PROs (cough frequency/severity) and breathlessness moved into key secondary category after encouraging CORAL findings, strengthening potential label-relevant data.
Regulatory and Safety Preparations
Agreement with FDA on remaining standard label-enabling Phase I studies (renal/hepatic impairment, food effect) and DDI assessments (including interaction with new antifibrotic nerandomilast and CYP inducer/inhibitor studies) to support NDA.
Controlled-Substance/Scheduling Outlook
Management reported constructive discussions with controlled-substances staff, submitted human abuse potential and respiratory safety data, and expressed growing conviction the product will remain unscheduled.
TRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 17, 2026 | $11.19 | $10.69 | -4.47% |
Nov 13, 2025 | $11.46 | $11.37 | -0.79% |
Aug 07, 2025 | $7.30 | $7.42 | +1.64% |
May 08, 2025 | $6.60 | $6.60 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Trevi Therapeutics Inc (TRVI) report earnings?
Trevi Therapeutics Inc (TRVI) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is Trevi Therapeutics Inc (TRVI) earnings time?
Trevi Therapeutics Inc (TRVI) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TRVI EPS forecast?
TRVI EPS forecast for the fiscal quarter 2026 (Q1) is -0.08.